Characterization of KRAS-driven survival signaling networks via phosphoproteomics in lung cancer.

被引：0
|
作者：
Kim, Jae-Young [1 ]
Welsh, Eric A. [1 ]
Fang, Bin [1 ]
Li, Jiannong [1 ]
Eschrich, Steven A. [1 ]
Koomen, John [1 ]
Haura, Eric B. [1 ]
机构：
[1] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
来源：
MOLECULAR CANCER THERAPEUTICS | 2013年 / 12卷 / 11期
关键词：
D O I：
10.1158/1535-7163.TARG-13-A61
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A61
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer
    Kitapma, Shunsuke
    Ivanova, Elena
    Guo, Sujuan
    Yoshida, Ryohei
    Campisi, Marco
    Sundararaman, Shrirarn K.
    Tange, Shoichiro
    Mitsuishi, Yoichiro
    Thai, Tran C.
    Masudaa, Sayuri
    Piel, Brandon P.
    Sholl, Lynette M.
    Kirschmeier, Paul T.
    Paweletz, Cloud P.
    Watanabe, Hideo
    Yajima, Mamiko
    Barbie, David A.
    CANCER DISCOVERY, 2019, 9 (01) : 34 - 45
  • [42] Toll-like receptor 2 deficiency enhances KRAS-driven lung cancer
    Liu, Chia-Hsin
    CANCER RESEARCH, 2018, 78 (13)
  • [43] The integrated stress response is tumorigenic and constitutes a therapeutic liability in KRAS-driven lung cancer
    Nour Ghaddar
    Shuo Wang
    Bethany Woodvine
    Jothilatha Krishnamoorthy
    Vincent van Hoef
    Cedric Darini
    Urszula Kazimierczak
    Nicolas Ah-son
    Helmuth Popper
    Myriam Johnson
    Leah Officer
    Ana Teodósio
    Massimo Broggini
    Koren K. Mann
    Maria Hatzoglou
    Ivan Topisirovic
    Ola Larsson
    John Le Quesne
    Antonis E. Koromilas
    Nature Communications, 12
  • [44] A one-two punch for KRAS-driven cancer
    Megan Cully
    Nature Reviews Drug Discovery, 2015, 14 : 600 - 600
  • [45] Arf suppresses the growth and progression of Kras-driven lung tumors
    Busch, Stephanie E.
    Gurley, Kay E.
    Moser, Russell D.
    Kelly-Spratt, Karen S.
    Kemp, Christopher J.
    CANCER RESEARCH, 2011, 71
  • [46] Epigenetic activation of IGF1R signaling promotes resistance to momelotinib and MEK inhibition in KRAS-driven lung cancer
    Kitajima, Shunsuke
    Asahina, Hajime
    Cavanaugh, Jillian D.
    Chen, Ting
    Merlino, Ashley A.
    Tran, Thai C.
    Wong, Kwonk-Kin
    Barbie, David A.
    CANCER RESEARCH, 2016, 76
  • [47] Targeting platelets for improved outcome in KRAS-driven lung adenocarcinoma
    Stephanie R. Hyslop
    Marliese Alexander
    Alesha A. Thai
    Ariena Kersbergen
    Andrew J. Kueh
    Marco J. Herold
    Jason Corbin
    Pradnya Gangatirkar
    Ashley P. Ng
    Benjamin J. Solomon
    Warren S. Alexander
    Kate D. Sutherland
    Emma C. Josefsson
    Oncogene, 2020, 39 : 5177 - 5186
  • [48] A systems biology approach to elucidate the mechanism of EGFR inhibitor sensitivity in mutant KRAS-driven colorectal cancer.
    McFall, Thomas
    Diedrich, Jolene
    Littlechild, Stacy L.
    Sisk-Hackworth, Laura
    Moresco, James
    Mengistu, Meron
    Shaw, Andrey
    Stites, Ed
    MOLECULAR CANCER RESEARCH, 2020, 18 (05) : 73 - 73
  • [49] PTPN2 regulates the activation of KRAS and plays a critical role in proliferation and survival of KRAS-driven cancer cells
    Huang, Zhangsen
    Liu, Mingzhu
    Li, Donghe
    Tan, Yun
    Zhang, Ruihong
    Xia, Zhizhou
    Wang, Peihong
    Jiao, Bo
    Liu, Ping
    Ren, Ruibao
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2020, 295 (52) : 18343 - 18354
  • [50] Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma
    Ambrogio, Chiara
    Gomez-Lopez, Gonzalo
    Falcone, Mattia
    Vidal, August
    Nadal, Ernest
    Crosetto, Nicola
    Blasco, Rafael B.
    Fernandez-Marcos, Pablo J.
    Sanchez-Cespedes, Montserrat
    Ren, Xiaomei
    Wang, Zhen
    Ding, Ke
    Hidalgo, Manuel
    Serrano, Manuel
    Villanueva, Alberto
    Santamaria, David
    Barbacid, Mariano
    NATURE MEDICINE, 2016, 22 (03) : 270 - 277
12345